Tandem vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Reached $1B valuation (2026). Automates specialty drug prior auth, access barriers, and copay assistance for providers. Targets $500B+ specialty drug access bottleneck.
About
Tandem is a specialty drug access automation platform that has reached a $1 billion valuation in 2026, providing AI-powered automation of the full specialty pharmaceutical access workflow for healthcare providers — prior authorization submissions, access barrier management, copay assistance enrollment, and patient assistance program identification. The platform targets the $500+ billion specialty drug market where access friction is the primary barrier preventing patients from receiving prescribed medications.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.